Copertina

Oral decitabine–cedazuridine in acute myeloid leukaemia

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ian M. Bouligny, Courtney D. DiNardo
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
di: Klaus Geissler, et al.
Pubblicazione: (2024)

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
di: Michael R. Savona, et al.
Pubblicazione: (2025)

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
di: Wei‐Ying Jen, et al.
Pubblicazione: (2024)

Sweet's syndrome in acute myeloid leukaemia
di: Hsu T. Mon, et al.
Pubblicazione: (2026)

Immunophenotypic clustering in paediatric acute myeloid leukaemia
di: Hui Liu, et al.
Pubblicazione: (2024)

Preclinical activity of resazurin in acute myeloid leukaemia
di: Trung Quang Ha, et al.
Pubblicazione: (2024)

The Menin story in acute myeloid leukaemia—The road to success
di: Michael W. M. Kühn, et al.
Pubblicazione: (2024)

Leucostasis‐induced limb ischaemia in acute myeloid leukaemia
di: Yorick Sandberg, et al.
Pubblicazione: (2025)

Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
di: Boaz Nachmias, et al.
Pubblicazione: (2024)

Masked critical thrombocytopenia in hypercellular acute myeloid leukaemia
di: Wing Kit Lam, et al.
Pubblicazione: (2026)

Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications
di: Sean Harrop, et al.
Pubblicazione: (2024)

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia
di: Alexandra Dreyzin, et al.
Pubblicazione: (2025)

ZIP10 as a potential therapeutic target in acute myeloid leukaemia
di: Benjamin Rolles, et al.
Pubblicazione: (2025)

Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
di: Boaz Nachmias, et al.
Pubblicazione: (2025)

Immune‐deficient MISTRG mice support expansion of leukaemia‐initiating cells in xenograft models of paediatric acute myeloid leukaemia
di: Patrick Connerty, et al.
Pubblicazione: (2025)

Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
di: Peiqi Liang, et al.
Pubblicazione: (2024)

A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction
di: Cesar Alexander Ortiz Rojas, et al.
Pubblicazione: (2024)

The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
di: Shyam A. Patel
Pubblicazione: (2024)

Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia
di: Li‐Xin Wu, et al.
Pubblicazione: (2025)

Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all
di: Felicetto Ferrara
Pubblicazione: (2026)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
di: Isla M. Johnson, et al.
Pubblicazione: (2024)

Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML ‐001 trial
di: Maria Teresa Voso, et al.
Pubblicazione: (2025)

Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
di: Francesca A. M. Kinsella, et al.
Pubblicazione: (2024)

The Mozart effect in chronic myeloid leukaemia
di: Jesper Stentoft
Pubblicazione: (2024)

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013–2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy
di: Takaaki Konuma, et al.
Pubblicazione: (2025)

Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights
di: Lin‐Ya Wang, et al.
Pubblicazione: (2025)

Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO‐DBH AML study
di: Morten Krogh Herlin, et al.
Pubblicazione: (2025)

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis
di: Huimin Jin, et al.
Pubblicazione: (2025)

An old leukaemia in young patients—Genetic characteristics of paediatric chronic myeloid leukaemia
di: Markus Metzler, et al.
Pubblicazione: (2025)

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia
di: Laura Monaghan, et al.
Pubblicazione: (2026)

A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia
di: Thierry Soussi, et al.
Pubblicazione: (2025)

Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia
di: Eva Crespo‐García, et al.
Pubblicazione: (2026)

Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia
di: Pierre‐Yves Sansen, et al.
Pubblicazione: (2024)

Combining 5‐azacitidine with the E‐selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia
di: Anoop K. Enjeti, et al.
Pubblicazione: (2024)

Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline‐containing chemotherapy: A population‐based matched cohort study
di: Rikke Hedegaard Jensen, et al.
Pubblicazione: (2025)

Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial ( JCCG AML ‐12)
di: Tomoya Komori, et al.
Pubblicazione: (2026)

Real‐world experience with CPX ‐351 for secondary acute myeloid leukaemia: Comparison with FLAG ‐ IDA in a propensity score matching analysis
di: Maria Agustina Perusini, et al.
Pubblicazione: (2025)

Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single‐centre retrospective study
di: Shuqi Zhao, et al.
Pubblicazione: (2024)

POU6F2, a novel fusion partner of NUP98 in acute myeloid leukaemia: A case report
di: Yu Jeong Choi, et al.
Pubblicazione: (2024)

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
di: Barbora Weinbergerová, et al.
Pubblicazione: (2024)